TrialRespiratory research2024

Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer.

Chenyue Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.